Navigation Links
Genetic medicine and AMD treatment; genetic screening and glaucoma
Date:10/17/2010

CHICAGO Genetic medicine is the focus of two presentations at today's Scientific Program of the 2010 American Academy of Ophthalmology (AAO) Middle East-Africa Council of Ophthalmology (MEACO) Joint Meeting. The AAO-MEACO meeting is in session October 16 through 19 at McCormick Place, Chicago. It is the largest, most comprehensive ophthalmic education conference in the world.

Seeking Genetics-Specific Treatments for Age-Related Macular Degeneration

In the past decade ophthalmologists gained a powerful tool to control vision-damaging "wet" age-related macular degeneration (wet AMD): anti-vascular endothelial growth factor (anti-VEGF) medications. Anti-VEGF drugs halt or even reverse damage in many wet AMD patients, but some do not respond as well to treatment and so suffer severe vision loss. The new field of pharmacogenetics seeks to enable doctors to individualize treatment based on the patient's genetic profile for a disease. In a collaborative effort, the Hussman Institute for Human Genomics and Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine studied whether specific genetic AMD risk factors and/or smoking influenced patients' responses to anti-VEGF treatment.

The researchers reviewed medical records of 36 people with wet AMD who participated in the Unifying Genetic Epidemiology of Macular Degeneration Study. In terms of anti-VEGF treatment, there were 12 responders whose vision improved, 18 maintainers, and 6 poor responders whose vision declined. All patients had been treated with bevacizumab (Avastin) and/or ranibizumab (Lucentis) for at least one year. None of the patients had vision loss due to cataract, geographic atrophy (advanced "dry" AMD), laser scar or retinal pigment epithelial tear. DNA analysis was done for two AMD-genetic risk factors: complement factor H (CFH) and age-related maculopathy susceptibility-2 (ARMS2) genes. Twenty-four patients had been smokers and three were current smokers. The average age was 80 years.

"Neither high risk genetic factors nor smoking history was significantly associated with patients' response to anti-VEGF therapy in our study," said Jaclyn L Kovach, MD. "However, more responders than poor responders carried at least one risk allele for ARMS2, CFH, or for both genes. Repeating this study in a larger population could bring us closer to a gene-guided therapy for wet AMD."

AMD is categorized as either "dry" or "wet." In the advanced "wet" form, abnormal new blood vessels develop under the retina that bleed or leak fluid and form scars. Advanced AMD destroys the detailed, central vision we need to recognize faces, read, drive, and enjoy daily life.

Genetic Screening Could Improve Glaucoma Care

Symptoms of glaucoma, a disease that destroys the optic nerve, can be so subtle that people often don't know they have the condition. About 4.3 million Americans have glaucoma, and doctors estimate that about half of them are unaware of it. Costs associated with treating the most common type of glaucoma now exceed $3 billion. Genetic screening could help catch glaucoma early on, so patients could be tracked and treated in time to save their sight. Janey L Wiggs, MD, PhD, of the Massachusetts Eye and Ear Infirmary, said genetic testing is currently able to indicate the presence of or risk for several types of glaucoma. Heredity plays a significant role in the disease.

"Blood or cheek cell samples would be collected from patients and appropriate family members, and then selected genes would be sequenced," said Dr. Wiggs. "We can identify markers for congenital glaucoma, early onset (before age 35) primary open angle glaucoma, and normal tension glaucoma, as well as several other conditions that increase glaucoma risk," she added.

Many more genetic markers may soon be available for use in screening for open angle glaucoma and other disease variants. Dr. Wiggs said the challenge will be to identify combinations of genes and/or environmental factors that will produce the most sensitive, specific screening tests.


'/>"/>

Contact: Mary Wade
mwade@aao.org
510-725-5677
American Academy of Ophthalmology
Source:Eurekalert

Related medicine news :

1. Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer
2. Obstructive Sleep Apnea in Kids May Have Genetic Cause
3. Epigenetic signals differ across alleles
4. Study reveals genetic link between mammographic density and breast cancer
5. Genetic Risk Score Doesnt Spot Heart Trouble in Women
6. Penn researchers find genetic link to leukemias with an unknown origin
7. Scientists Spot Genetic Fingerprints of Individual Cancers
8. Genetic health risks in children of assisted reproductive technology
9. Genetic Mutation Linked to Prostate Cancer in Blacks
10. Protecting the brain from of a deadly genetic disease
11. Protecting the brain from a deadly genetic disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... Raton, FL (PRWEB) , ... January 21, 2017 , ... ... Germany, announced it is bringing its product to the United States as part of ... over the last 25 years, Alcovit aims to reduce the productions of nasty toxins ...
(Date:1/21/2017)... ... January 21, 2017 , ... ... Relations, Dianne Travis-Teague, the electrifying line-up of events for its annual meeting “Coming ... friends, and community. “Coming Home 2017” will be held on Friday January ...
(Date:1/21/2017)... Austin, Texas (PRWEB) , ... January 21, 2017 ... ... surgeries performed by Austin, Texas Periodontist Dr. Dan Holtzclaw in media for its ... features two surgeries performed by Dr. Holtzclaw in which he utilizes creos™ ...
(Date:1/20/2017)... ... 20, 2017 , ... Source Vitál Apothecary, a skin and body care company ... the company had a successful visit to the 2017 ECRM Diet, Vitamin & Sports ... work in the nutritional, sports and health industries a chance to meet in private ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... to enhance people’s everyday lives, recently attended the January ECRM Trade Show in ... Science is known for its large range of supplements that keep the body ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... , Jan 20, 2017 Research ... Testing Market By Type ([CBC, HGB/HCT, BMP, BUN Creatinine, Electrolyte Testing, ... By End-use, And Segment Forecasts, 2013 - 2024" report to ... ... 198.5 billion by 2024 Introduction of innovative solutions on ...
(Date:1/20/2017)... Research and Markets has announced the addition of the ... to their offering. ... This research service on the global pharmaceutical stability testing market ... of the key participants in the market. The ... 2020. The market is expected to grow at a CAGR of ...
(Date:1/20/2017)... Avillion LLP, a co-developer and financier of late-stage pharmaceutical product ... as Chief Medical Officer. Dr Weinberg will be based in ... ... than 17 years as a pharmaceutical and biotech executive with experience ... course of his career, he has interfaced with the US Food ...
Breaking Medicine Technology: